Through our experimental results, we found that on FLT3-ITD (+) AML cell lines, compared to the monotherapy group, Apatinib and HHT could significantly inhibit cell proliferation, promote cell apoptosis, and regulate Apatinib-relevant protein VEGFR-2. The gene discussed is FLT3; the disease is acute myeloid leukemia.